Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII.

IF 1.9 4区 医学 Q3 RHEUMATOLOGY
Lupus Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI:10.1177/09612033241272953
Man Zhao, Leyao Ma, Xinwang Duan, Yuehong Huo, Shengyun Liu, Cheng Zhao, Zhaohui Zheng, Qian Wang, Xinping Tian, Yunzhuan Chen, Mengtao Li
{"title":"Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII.","authors":"Man Zhao, Leyao Ma, Xinwang Duan, Yuehong Huo, Shengyun Liu, Cheng Zhao, Zhaohui Zheng, Qian Wang, Xinping Tian, Yunzhuan Chen, Mengtao Li","doi":"10.1177/09612033241272953","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Thalidomide is an effective medication for refractory mucocutaneous lesions of systemic lupus erythematosus (SLE) and can treat arthritis in some autoimmune diseases, but it has some adverse reactions. Recently, the effectiveness of tofacitinib in treating mucocutaneous lesions of SLE has been reported. We aimed to compare the efficacy and safety of tofacitinib with thalidomide in treating mucocutaneous and musculoskeletal lesions in patients with SLE.</p><p><strong>Methods: </strong>This study was a real-world cohort study based on the Chinese SLE Treatment and Research group (CSTAR) registry. SLE patients who manifested mucocutaneous and/or musculoskeletal symptoms and were prescribed tofacitinib or thalidomide were included. We retrospectively conducted comparisons between the tofacitinib and thalidomide groups regarding clinical improvements, SLE disease activity, serological indicators, glucocorticoid doses, and adverse events at the 1, 3, and 6-months time points.</p><p><strong>Results: </strong>At 3 and 6 months, the tofacitinib group exhibited a higher proportion of patients with improvement in mucocutaneous and musculoskeletal issues. Additionally, a greater percentage of patients in the tofacitinib group achieved remission or a low disease activity state (LLDAS) at these time points. No significant serological improvements were observed in either the tofacitinib or thalidomide groups. Fewer adverse events were observed in the tofacitinib group than in the thalidomide group.</p><p><strong>Conclusions: </strong>Tofacitinib might be superior to thalidomide in the improvement of mucocutaneous and musculoskeletal lesions in SLE, and had a good safety profile.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lupus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09612033241272953","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Thalidomide is an effective medication for refractory mucocutaneous lesions of systemic lupus erythematosus (SLE) and can treat arthritis in some autoimmune diseases, but it has some adverse reactions. Recently, the effectiveness of tofacitinib in treating mucocutaneous lesions of SLE has been reported. We aimed to compare the efficacy and safety of tofacitinib with thalidomide in treating mucocutaneous and musculoskeletal lesions in patients with SLE.

Methods: This study was a real-world cohort study based on the Chinese SLE Treatment and Research group (CSTAR) registry. SLE patients who manifested mucocutaneous and/or musculoskeletal symptoms and were prescribed tofacitinib or thalidomide were included. We retrospectively conducted comparisons between the tofacitinib and thalidomide groups regarding clinical improvements, SLE disease activity, serological indicators, glucocorticoid doses, and adverse events at the 1, 3, and 6-months time points.

Results: At 3 and 6 months, the tofacitinib group exhibited a higher proportion of patients with improvement in mucocutaneous and musculoskeletal issues. Additionally, a greater percentage of patients in the tofacitinib group achieved remission or a low disease activity state (LLDAS) at these time points. No significant serological improvements were observed in either the tofacitinib or thalidomide groups. Fewer adverse events were observed in the tofacitinib group than in the thalidomide group.

Conclusions: Tofacitinib might be superior to thalidomide in the improvement of mucocutaneous and musculoskeletal lesions in SLE, and had a good safety profile.

治疗系统性红斑狼疮粘膜病变的托法替尼与沙利度胺:真实世界CSTAR队列研究XXVII。
目的:沙利度胺是治疗系统性红斑狼疮(SLE)难治性皮肤黏膜病变的有效药物,也可治疗某些自身免疫性疾病的关节炎,但它有一些不良反应。最近,有报道称托法替尼治疗系统性红斑狼疮皮肤黏膜病变有效。我们旨在比较托法替尼和沙利度胺治疗系统性红斑狼疮患者粘膜和肌肉骨骼病变的疗效和安全性:本研究是一项基于中国系统性红斑狼疮治疗研究组(CSTAR)登记的真实世界队列研究。纳入的系统性红斑狼疮患者均表现出粘膜和/或肌肉骨骼症状,并接受了托法替尼或沙利度胺治疗。我们回顾性地比较了托法替尼组和沙利度胺组在1、3和6个月时点的临床改善、系统性红斑狼疮疾病活动、血清学指标、糖皮质激素剂量和不良事件:结果:在3个月和6个月时,托法替尼组有较高比例的患者粘膜和肌肉骨骼问题得到改善。此外,托法替尼组在这些时间点达到缓解或低疾病活动状态(LLDAS)的患者比例更高。无论是托法替尼组还是沙利度胺组,都没有观察到明显的血清学改善。托法替尼组的不良反应少于沙利度胺组:结论:在改善系统性红斑狼疮患者的粘膜和肌肉骨骼病变方面,托法替尼可能优于沙利度胺,而且具有良好的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lupus
Lupus 医学-风湿病学
CiteScore
4.20
自引率
11.50%
发文量
225
审稿时长
1 months
期刊介绍: The only fully peer reviewed international journal devoted exclusively to lupus (and related disease) research. Lupus includes the most promising new clinical and laboratory-based studies from leading specialists in all lupus-related disciplines. Invaluable reading, with extended coverage, lupus-related disciplines include: Rheumatology, Dermatology, Immunology, Obstetrics, Psychiatry and Cardiovascular Research…
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信